News

Adding blinatumomab to consolidation chemotherapy provided a significant OS benefit in MRD-negative B-cell precursor acute lymphoblastic leukemia.

Ozuriftamab vedotin, an ROR2-targeted antibody drug conjugate, received fast track designation from the FDA for recurrent or metastatic head and neck squamous cell carcinoma.

Weighted blankets alleviated anxiety for patients with cancer undergoing infusions without interfering with their care.

Denileukin diftitox received FDA approval to treat relapsed/refractory cutaneous T-cell lymphoma previously treated with at least 1 systemic therapy.

NCCN guidelines have been updated to recommend imetelstat to treat symptomatic anemia in patients with lower-risk myelodysplastic syndromes.

Fast track designation has been granted from the FDA to HP518 to treat androgen receptor–positive triple-negative breast cancer.

This marks the first approval of a systemic therapy for patients with grade 2 astrocytoma or oligodendroglioma with an IDH1 or IDH2 mutation.

Atezolizumab was safe and effective when administered before and following chemoradiation in unresectable stage III non–small cell lung cancer.

Nivolumab plus tivozanib did not improve progression-free survival in patients with advanced metastatic renal cell carcinoma after prior immune checkpoint inhibition.

Men with metastatic hormone-sensitive prostate cancer treated with darolutamide plus ADT in the phase 3 ARANOTE trial had improved radiologic progression-free survival compared with placebo.

Pregnancies may be carried out and were successful in patients after undergoing allogeneic hematopoietic cell transplantation.

Treatment with paxalisib in patients with newly diagnosed unmethylated glioblastoma was well tolerated with no new safety signals.

Fast track designation has been awarded by the FDA to the next-generation precision radiopharmaceutical therapy ABD-147 to treat extensive-stage small cell lung cancer.

Crofelemer missed the diarrhea endpoint in a study assessing prophylaxis in adult patients with solid tumors receiving targeted therapy.

Accelerated approval has been granted by the FDA to afamitresgene autoleucel for certain patients with pretreated unresectable or metastatic synovial sarcoma.

A dostarlimab-gxly combination was approved for advanced or recurrent endometrial cancer.

Donna Catamero, ANP-BC, OCN, CCRC, discusses the importance of quickly identifying and managing adverse effects from CAR T-cell therapy in patients with multiple myeloma.

Developing a strong working relationships and understanding the physical and emotional demands of the oncology specialty are some ways nurses can address burnout, an expert said.

The progression-free survival benefit with belzutifan was observed across subgroups of patients with pretreated advanced clear cell renal cell carcinoma.

Based on in vitro studies, this tetravalent bispecific antibody may show binding affinity to PD1 and VEGF.

Darzalex Faspro plus VRd was approved by the FDA for induction and consolidation in newly diagnosed multiple myeloma eligible for ASCT.

Taking mismatched unrelated donors into consideration may increase donor numbers, especially for patients with minority ancestry who are seeking hematopoietic cell transplantation.

The FDA approved the Shield blood test for colorectal screening in adults aged 45 years and older with an average risk for the disease.

A fixed-duration treatment combining acalabrutinib and venetoclax, with or without obinutuzumab, significantly extended progression-free survival in patients with previously untreated chronic lymphocytic leukemia.

Findings from this study also demonstrate statistically meaningful improvements in breast cancer–specific quality of life and endocrine symptoms with acupuncture.

The TIL cell therapy OBX-115 received fast track designation from the FDA for locally advanced or metastatic melanoma.

The antibody drug conjugate BNT324/DB-1311 received fast track designation for the potential treatment of unresectable advanced or metastatic castration-resistant prostate cancer with disease progression.

Findings from the RATIONALE-306 trial support treatment of tislelizumab plus chemotherapy for PD-L1-positive ESCC.

Adding dostarlimab to chemotherapy improved survival vs chemo alone in primary advanced or recurrent endometrial cancer.

Perioperative pembrolizumab plus chemotherapy improves overall survival in patients with resectable gastric cancer.